Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety.

Francis JN, Bunce CJ, Horlock C, Watson JM, Warrington SJ, Georges B, Brown CB.

Vaccine. 2015 Jan 3;33(2):396-402. doi: 10.1016/j.vaccine.2014.06.006.

2.

Safety and immunogenicity of a plant-produced recombinant monomer hemagglutinin-based influenza vaccine derived from influenza A (H1N1)pdm09 virus: a Phase 1 dose-escalation study in healthy adults.

Cummings JF, Guerrero ML, Moon JE, Waterman P, Nielsen RK, Jefferson S, Gross FL, Hancock K, Katz JM, Yusibov V; Fraunhofer USA Center for Molecular Biotechnology Study Group..

Vaccine. 2014 Apr 17;32(19):2251-9. doi: 10.1016/j.vaccine.2013.10.017.

PMID:
24126211
3.

Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.

Combadière B, Vogt A, Mahé B, Costagliola D, Hadam S, Bonduelle O, Sterry W, Staszewski S, Schaefer H, van der Werf S, Katlama C, Autran B, Blume-Peytavi U.

PLoS One. 2010 May 26;5(5):e10818. doi: 10.1371/journal.pone.0010818.

4.

Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency.

van Assen S, de Haan A, Holvast A, Horst G, Gorter L, Westra J, Kallenberg CG, Telgt DS, Palache AM, Giezeman KM, Bijl M.

Clin Immunol. 2011 Nov;141(2):161-8. doi: 10.1016/j.clim.2011.07.004.

PMID:
21889412
5.

Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.

Rudenko L, Kiseleva I, Stukova M, Erofeeva M, Naykhin A, Donina S, Larionova N, Pisareva M, Krivitskaya V, Flores J; Russian LAIV Trial Study Group..

Vaccine. 2015 Sep 22;33(39):5110-7. doi: 10.1016/j.vaccine.2015.08.019.

PMID:
26296497
6.

Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.

Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, Buzitskaya Z, Isakova-Sivak I, Kuznetsova S, Larionova N, Desheva J, Dubrovina I, Nikiforova A, Victor JC, Neuzil K, Flores J, Tsvetnitsky V, Kiselev O.

PLoS One. 2014 Feb 12;9(2):e87962. doi: 10.1371/journal.pone.0087962.

7.

Epitope specific T-cell responses against influenza A in a healthy population.

Savic M, Dembinski JL, Kim Y, Tunheim G, Cox RJ, Oftung F, Peters B, Mjaaland S.

Immunology. 2016 Feb;147(2):165-77. doi: 10.1111/imm.12548.

PMID:
26489873
8.

Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus.

Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, Palache A, Wilschut J, Kallenberg CG, Bijl M.

Arthritis Rheum. 2009 Aug;60(8):2438-47. doi: 10.1002/art.24679.

9.

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.

Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017.

PMID:
19835828
10.

Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial.

Pleguezuelos O, Robinson S, Stoloff GA, Caparrós-Wanderley W.

Vaccine. 2012 Jun 29;30(31):4655-60. doi: 10.1016/j.vaccine.2012.04.089.

PMID:
22575166
11.

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC.

Clin Infect Dis. 2011 Jan 1;52(1):1-7. doi: 10.1093/cid/ciq015.

12.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099.

PMID:
21816199
13.

Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees.

Herrera MT, Gonzalez Y, Juárez E, Hernández-Sánchez F, Carranza C, Sarabia C, Guzman-Beltran S, Manjarrez ME, Muñoz-Torrico M, Garcia-Garcia L, Sada E, Torres M.

BMC Infect Dis. 2013 Nov 15;13:544. doi: 10.1186/1471-2334-13-544.

14.

A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.

Tameris M, Hokey DA, Nduba V, Sacarlal J, Laher F, Kiringa G, Gondo K, Lazarus EM, Gray GE, Nachman S, Mahomed H, Downing K, Abel B, Scriba TJ, McClain JB, Pau MG, Hendriks J, Dheenadhayalan V, Ishmukhamedov S, Luabeya AK, Geldenhuys H, Shepherd B, Blatner G, Cardenas V, Walker R, Hanekom WA, Sadoff J, Douoguih M, Barker L, Hatherill M.

Vaccine. 2015 Jun 9;33(25):2944-54. doi: 10.1016/j.vaccine.2015.03.070.

PMID:
25936724
15.

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.

Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW.

Vaccine. 2004 Aug 13;22(23-24):3136-43.

PMID:
15297066
16.

Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans.

Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, Tingley DW, Kabongo ML, Tucker SN.

Vaccine. 2013 Mar 25;31(13):1752-8. doi: 10.1016/j.vaccine.2013.01.023.

PMID:
23357198
17.

Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.

Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.

Pediatr Infect Dis J. 2012 May;31(5):494-500. doi: 10.1097/INF.0b013e31824bb179.

PMID:
22301476
18.

Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.

Zinckgraf JW, Sposato M, Zielinski V, Powell D, Treanor JJ, von Hofe E.

Vaccine. 2009 Aug 27;27(39):5393-401. doi: 10.1016/j.vaccine.2009.06.081.

PMID:
19596415
19.

Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2.

Posavad CM, Magaret AS, Zhao L, Mueller DE, Wald A, Corey L.

Vaccine. 2011 Sep 16;29(40):7058-66. doi: 10.1016/j.vaccine.2011.07.028.

20.

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A.

Vaccine. 2011 Jul 18;29(32):5145-52. doi: 10.1016/j.vaccine.2011.05.041.

PMID:
21624416
Items per page

Supplemental Content

Support Center